Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

119136 Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: (2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine

119136
Purchase on Sigma-Aldrich

概述

Replacement Information

Products

产品目录编号包装 数量 / 包装
119136-10MGCN 玻璃瓶 10 mg
Description
OverviewAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
Catalogue Number119136
Brand Family Calbiochem®
Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
References
ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
Product Information
CAS number37739-05-2
FormWhite solid
Hill FormulaC₁₅H₂₀ClN₅O₄
Chemical formulaC₁₅H₂₀ClN₅O₄
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetA1
Primary Target K<sub>i</sub>2.3 nM
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
119136-10MGCN 04055977223323

Documentation

Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem MSDS

职位

物料安全数据表 (MSDS) 

Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem 分析证书

标题批号
119136

参考

参考信息概述
Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision28-March-2013 JSW
Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
DescriptionAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number37739-05-2
Chemical formulaC₁₅H₂₀ClN₅O₄
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (100 mM) or H₂O (5 mM)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.